Imaavy approved in EU to treat gMG patients 12 and older
Imaavy (nipocalimab) has been approved in the European Union as an add-on to standard of care treatment for adults…
Andrea Lobo is a Science writer at Bionews since 2022. She holds a PhD in Cell Biology/Neurosciences, where she studied the molecular pathways that contribute to neurodegeneration/neuroprotection in stroke biology. Between 2011 and 2021, she worked as a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, focused on the molecular mechanisms involved in drug addiction, particularly neuronal plasticity and remodeling induced by amphetamines. As a research scientist for 19 years, Andrea also participated in academic projects in other research fields, including gene regulation, cancer, and rare diseases. During her professional journey, Andrea also developed her science writing skills by writing/editing scientific papers and grant proposals.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Imaavy (nipocalimab) has been approved in the European Union as an add-on to standard of care treatment for adults…
Anxiety related to COVID-19 is more prevalent among people with myasthenia gravis (MG) than among the general population, a…
People with refractory myasthenia gravis (MG) who fail to respond to several treatments may be effectively treated with…
Certain inflammatory molecules known as cytokines may play a role in a person’s risk of developing myasthenia gravis (MG), according…
Surgery to remove the thymus gland led to a long-term reduction in levels of immune T-cells and to temporary changes…
A higher body mass index (BMI), a measure of body fat based on height and weight, is associated with an…
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 2 clinical trial testing IM-101, ImmunAbs’…
The first patient has joined a Phase 3 clinical trial assessing the safety and efficacy of Descartes-08, an investigational…
People with generalized myasthenia gravis (gMG) who were misdiagnosed at least once and who have certain disease symptoms are…
Rituximab may be safe and effective in treating young children with myasthenia gravis (MG) driven by antibodies that…
Get regular updates to your inbox.